Q-omics provides the consensus-scored PAMR1 profile across patient tissues and cancer cell-line models. PAMR1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, PAMR1 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, PAMR1 protein abundance shows 21,103 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCEC, THCA, and LSCC as cancer lineages where PAMR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PAMR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PAMR1 survival associations across molecular data types. PAMR1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PAMR1 RNA expression–survival associations across cancer types. High PAMR1 expression shows unfavorable associations in KIRP, STAD and LGG, but favorable associations in UCEC, THCA and KIRC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for PAMR1 RNA expression.
This table summarizes PAMR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PAMR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PAMR1 shows lower tumor expression in THCA, COAD, KICH, BRCA, BLCA and LIHC. The THCA box plot shows higher PAMR1 RNA expression in normal versus tumor tissue (log2 FC = −2.387, t-test p < 0.001).
This table shows molecular features associated with PAMR1 in patient tissues and cancer cell lines. In patient samples, PAMR1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PAMR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
